二丙酸倍氯米松联合酮替芬防治毛细支气管炎后婴幼儿哮喘的研究

目的　观察低剂量二丙酸倍氯米松和酮替芬联合应用能否降低毛细支气管炎后支气管哮喘患病率。方法　 5 6例毛细支气管炎患儿为治疗组 ,采用低剂量二丙酸倍氯米松局部吸入 ,口服酮替芬 ,疗程 6～ 9个月 ;32例毛细支气管炎患儿不用药作为对照组。临床随访≥ 1年 ,观察两组患儿哮喘发生率。同时检测治疗前、后患儿肺功能及骨密度。结果　完成随访 1年以上者 ,治疗组 5 2例中仅 3例 (5 77% )发生哮喘 ,而对照组 30例中有 14例 (4 6 6 7% )发生哮喘 ,两组比较有显著性差异 (P <0 0 1)。治疗组患儿肺功能与治疗前比较亦有显著性差异。两组骨密度检测治疗前、后比较无显著差异。结论　低剂量二丙酸倍氯米松局部吸入与酮替芬联合应用可降低毛细支气管炎后婴幼儿哮喘患病率     

Controlled-release codeine is equivalent to acetaminophen plus codeine for post-cholecystectomy analgesia

PURPOSE: Following ambulatory surgery, long-acting analgesics may provide advantages over short-acting analgesics. This study compared controlled-release codeine (CC) and acetaminophen plus codeine (A/C; 300 mg/30 mg) for pain control in the 48-hr period following laparoscopic cholecystectomy. METHODS: Eligible patients were randomized to CC or A/C in a double-blind, double-dummy parallel group study. Unrelieved pain in hospital was treated with fentanyl i.v. bolus. Pain [100 mm visual analogue scale (VAS)] was assessed before the first dose of medication; at 0.5, one, two, three, and four hours post-dose; at discharge; and three times a day for 48 hr. Adverse events were recorded and measures of patient satisfaction were assessed at the end of the study. RESULTS: Eighty-four patients were enrolled in the study; 42 patients in each group. There were no statistically significant differences between CC and A/C treatment. Mean VAS baseline pain was similar in both groups (P = 0.49) and there was no significant difference in the time to onset of analgesia (P = 0.17). At 0.5 hr, the mean VAS pain score was significantly reduced from baseline in both groups (P = 0.0001). The VAS pain scores at discharge were reduced 59% and 56% from baseline, respectively (P = 0.61). There was no difference between treatments in the incidence of adverse events and patients reported similar levels of satisfaction. CONCLUSIONS: Controlled-release codeine provides an equivalent onset of analgesia, reduction in postoperative pain, and level of patient satisfaction, to acetaminophen plus codeine, over 48 hr following cholecystectomy, with the advantage of less frequent dosing.     

Recombinant tissue-plasminogen activator (rt-PA) in acute myocardial infarction in the Chinese in Hong Kong.

Eighty-nine consecutive Chinese patients (69 males, 20 females) with acute myocardial infarction treated by 100 mg recombinant tissue-plasminogen activator (rt-PA) (7 intracoronarily, 82 intravenously) at 3.7 +/- 1.0 hours after onset, and intravenous heparin or dipyridamole therapy started at 3 hours, were studied prospectively. Their mean age was 59.6 +/- 10.6 years. Forty-six patients (51.7%) had anterior and 39 patients (43.8%) had inferior infarcts. Clinical evidence of reperfusion was seen in 63 patients (72.8%), while new complications included hypotension (5.6%), heart failure (6.7%), cardiac arrhythmias (76.4%), hematoma around vascular access sites (23.6%), melena (2.2%) and cerebral infarction (2.2%). Maximal changes in coagulation profiles were seen at 3 hours, including a decrease in fibrinogen (by 64.2%), an increase in FDP by 11.7 times and D-dimers by 4.4 times. Nine patients (10.1%) had recurrence of angina and 6 patients (6.9%) died due to pump failure (5) and reinfarction (1). Angiogram at 14 days confirmed TIMI (2 or 3) patency of infarct related arteries in 62/81 (76.5%) patients, with a mean global ejection fraction of 52.5 +/- 12.4%. Nearly all survivors could maintain class I-II functional status after discharge. The safety and promises of rt-PA for acute myocardial infarction in the Chinese were confirmed.

     

K562／ADM耐药细胞株的建立及其生物学特性的初步观察

我们建立的K562/ADM耐药细胞株,在ADM浓度为2.4μg/m1(4.46μM)中已稳定培养3.5个月,传了30—35代,K562/ADM亦具有多药耐受件(Multidrug Resistance,MDR)的特点,对ADM、VCR、AT—1258和DDP的耐受性分别为K562的114.7、94.0、13.3和7.4倍,但对5—FU不产生交叉耐药。K562和K562/ADM的倍增时间分别为19.2h和52.8h,集落生成率分别为37.5％和11.1％,K562染色体数为34—68,中位数为56;K562/MDM染色体数为32—90,中位数为50,K562/ADM可做为耐药机理和克服耐药措施研究的极好模型。     

刺激兔扣带回对尾核头部痛相关单位电活动的影响

实验在15只家兔上进行。以玻璃微电极记录尾核头部(DHCN)痛相关单位,刺激扣带回,观察痛相关单位电活动的变化。在70只DHCN痛相关单位中,有44个对刺激扣带回表现兴奋反应(62.9％),17个呈抑制反应(24.3％),9个变化不明显(12.8％)。进一步观察了52只痛相关单位,在刺激扣带回后再施伤害刺激,43个原痛兴奋单位中15个转为抑制(34.9％),16个进一步兴奋(37.2％)12个无变化(27.9％);原9个痛抑制单位,8个转为兴奋,1个变化不明显。提示,扣带回可通过其下行活动,调制伤害性冲动在尾核水平上的传递。     

新疆奎屯地区口腔粘膜疾病调查

本文介绍新疆奎屯地区常见口腔粘膜疾病患病情况,其罹患率与上海地区同类调查相比,除白斑外其他病种罹患率均偏高,可能与生活水平偏低或某些全身疾病有关。     

Rat liver regeneration after partial hepatectomy: effects of insulin, glucagon and epidermal growth factor.

This study evaluated the role of insulin, glucagon and the epidermal growth factor (EGF) on liver regeneration after partial hepatectomy. Male Wistar rats, weighing approximately 200 g, were used. A partial hepatectomy, with resection of the medial and left lateral lobes (67.31%), was performed on the control group and seven hormone-treated groups: insulin, glucagon, EGF, insulin plus glucagon, insulin plus EGF, glucagon plus EGF, and a combination of the three hormones. The hormones were administered subcutaneously two days prior to the partial hepatectomy. The groups administered insulin were allowed to drink 20% glucose in water. Another group of rats received simulated operations, i.e., only a laparotomy was performed. The rats were killed at six, 24, 48 and 72 hours after the operation. Remnant liver weight, deoxyribonucleic acid (DNA) content, rate of DNA synthesis, mitotic index, blood glucose and serum insulin levels were measured. The results showed that: 1) the effects of single hormone administration on posthepatectomy liver regeneration were not obvious; 2) combined administration of insulin and glucagon increased the weight of the remnant liver, the DNA content, and the rate of DNA synthesis; 3) the combined administration of insulin, glucagon, and EGF increased the regeneration based on the remnant liver weight and mitotic index; and 4) there was no concordance between the change in blood glucose levels and the effect of hormones during liver regeneration.     

Effects of alkyl chain length on the inhibition of NNK-induced lung neoplasia in A/J mice by arylalkyl isothiocyanates

Six homologous arylalkyl isothiocyanates were evaluated fortheir abilities to inhibit pulmonary adenomas induced by thetobacco-specific nitrosamine 4-(methylnitrosamino)-l-(3-pyridyl)-1-butanone(NNK) in A/J mice. Four consecutive daily doses (5 µmol/mouse)of phenyl isothiocyanate (PITC), benzyl isothiocyanate (BITC),phenethyl isothiocyanate (PETTC), 3-phenylpropyl isothiocyanate(PPITC), 4-phenylbutyl isothiocyanate (PBITC), 4-oxo-4-(3-pyridyl)-butylisothiocyanate (OPBITC) and corn ofl were administered to miceby gavage. Two hours following the final dosing, mice were administeredsaline or 10 µmol of NNK in saline i.p. Pulmonary adenomaswere counted at 16 weeks after NNK administration. The miceadministered only corn oil prior to NNK developed an averagemultiplicity of 9.2 tumors/ mouse. Pretreatment with PITC, BITCand OPBITC had no significant effects on NNK-induced lung neoplasia.However, PEITC pretreatment resulted in a 64% reduction of lungtumor multiplicity, but did not affect the percentage of micethat developed tumors. Both PPITC and PBITC decreased tumormultiplicity by 96% and the percentage of tumor-bearing animalsby >60%. These results, in conjunction with our previouswork, demonstrate a general trend of increasing inhibition ofNNK-induced lung neoplasia by arylalkyl isothiocyanates withincreasing alkyl chain length. This study also demonstratesthe remarkable inhibitory activities of PPITC and PBITC, twoisothiocyanates that had not previously been tested as chemopreventiveagents.